Advertisement

Inhibition of 5-lo Activating Protein (Flap) Activity Decreases Proteinuria in Streptozotocin(Stz)-induced Diabetic Rats.

  • José M. Valdivielso
  • Angel Montero
  • Karen A. Munger
  • Kamal F. Badr
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 507)

Abstract

Proteinuria is a major cause of morbidity in patients with glomerular disease. Nonselective protein filtration is now recognized as a significant contributing factor to the tubulo-interstitial injury which underlies and often predicts progressive renal insufficiency in patients with primary glomerular diseases. Increasing recognition of the mechanisms whereby proteinuria leads to tubule injury confirms the well-known clinical observation that the magnitude of proteinuria at diagnosis is a reliable predictor of prognosis in patients with glomerulonephritis and diabetes. For this reason, the search for safe and effective anti-proteinuric agents which do not reduce the glomerular filtration rate represents an urgent and critical need for physicians involved in the care of patients with glomerular disorders.

Keywords

Blood Urea Nitrogen Proliferative Glomerulonephritis Significant Contribute Factor Tubule Injury Progressive Renal Insufficiency 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    D. K. Miller, J. W. Gillard, P. J. Vickers, S. Sadowski, C. Leveille, J. A. Mancini, P. Charleson, R. A. F. Dixon, A. W. Ford-Hutchinson, R. Fortin, J. Y. Gauthier, J. Rodkey, R. Rosen, C. Rouzer, I. S. Sigal, C. D. Strader, and J. F. Evans. Identification and isolation of a membrane protein necessary for leukotriene production.Nature343: 278–281, (1990).PubMedCrossRefGoogle Scholar
  2. 2.
    R. A. F. Dixon, R. E. Diehl, E. Opas, E. Rands, P. J. Viskers, J. F. Evans, J. W. Gillard, and D. K. Miller. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.Nature343: 282–284, (1990).PubMedCrossRefGoogle Scholar
  3. 3.
    S. Uda, K. A. Munger, and K. F. Badr. Glomerular localization of 5-lipoxygenase (5-LO) and 5-LO activating protein (FLAP) in a rat model of proliferative glomerulonephritis.J Am Soc Nephrol8, (1997).Google Scholar
  4. 4.
    A. Guash, C. F. Zayas, and K. F. Badr. MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis.Kidney /nt56, (1999).Google Scholar
  5. 5.
    S. Shankland, and J. Scholey. Expression of transforming growth factor-(31 during diabetic renal hypertrophy.Kidney /nt46: 430–442, (1994).CrossRefGoogle Scholar
  6. 6.
    J. Valdivielso, F. Perez-Barriocanal, J. García-Estañ, and J. López-Novoa. Role of nitric oxide in the early renal hemodynamic response after unilateral nephrectomy.American Journal of Physiology276: R1718- R1723, (1999).Google Scholar
  7. 7.
    K. Munger, A. Montero, M. Fukunaga, S. Uda, T. Yura, E. Imai, Y. Kaneda, J. Valdivielso, and K. Badr. Transfection of rat kidney with human 15-lipoxigenase suppresses inflammation and preserves function in experimental glomerulonephritis.PNAS96: 13375–13380, (1999).PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    R. Arison, E. Ciaccio, M. Glitzer, J. Cassaro, and M. Pruss. Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin.Diabetes16: 51–56, (1967).PubMedGoogle Scholar
  9. 9.
    A. Junod, A. Lambert, L. Orci, R. Pictet, A. Gonet, and A. Renold. Studies of the diabetogenic action of streptozotocin.Proc Soc Exp Biol Med126: 201–205, (1967).PubMedCrossRefGoogle Scholar
  10. 10.
    H. Selawry, J. Pennell, V. Pardo, D. Alzamora, and M. Millard. The effect of culture-mantained pancreatic islets on metabolic parameters, renal function, and glomerular lesions in the diabetic rat.Metabolism29: 261–269, (1980).PubMedCrossRefGoogle Scholar
  11. 11.
    R. Weil, M. Nozawa, M. Koss, C. Weber, K. Reemstsama, and R. McIntosh. The kidney in streptozotocin diabetic rats.Arch Pathol Lab Med100: 37–49, (1976).PubMedGoogle Scholar
  12. 12.
    J. Sheth. Diabetes, micrfoalbuminuria and hypertension.Clin and Exper Hypertension21: 61–68, (1999).CrossRefGoogle Scholar
  13. 13.
    V. Stewart, P. Whithing, A. Bell, and G. Hawsworth. Streptozotozin-induces diabetes is associated with increased renal lipoxygenase activity.Biochem Soc Transac26: S 134, (1998).Google Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • José M. Valdivielso
    • 1
  • Angel Montero
    • 1
  • Karen A. Munger
    • 1
  • Kamal F. Badr
    • 1
  1. 1.Center for GlomerulonephritisEmory University School of MedicineAtlanta

Personalised recommendations